한국어
Quantus

ChoA Pharmaceutical

034940 · KOSDAQ
₩2,835+0.89%
2026-09-04 close

ChoA Pharmaceutical last closed at ₩2,835 (+0.89%) on 2026-09-04. Listed on KOSDAQ; price, financials and dividends update daily after market close.

Loading chart…
Close
No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
303 picks
Next-day win rate
50.7%
Avg next-day
-0.11%
vs market
-0.49%p

Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

C
Overall: 건강관리 217/291 · top 75%
Factor composite · relative position in sector

PER — · PBR 0.56 — own-history percentile 0/100 · 100/100

Open self-history band
PER0/100
PBR100/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -1.99
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
-1.99
Beneish M-Score
-2.95

No statistical flag

Sloan accrual
-7.20%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Why has this company moved this way?

Auditable observations with the original numeric evidence.

매출 하락 → 마진 압박 → 현금 악화

Critical

매출이 -0.4% 감소하며 영업이익률이 -14.0%에서 -15.5%로 하락했다. 영업현금흐름도 동반 감소하여 수익-현금 순환이 약화되고 있다.

Evidence

매출 YoY -0.4% (2023→2024)영업이익률 -14.0%→-15.5%영업CF -1,475→-4,468

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

3/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score3/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROAPass
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtNot passed
  • Higher current ratioNot passed
  • No new sharesNot passed

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Industry structure

KRAs of 2026-09-05

건강관리

This stock is in 건강관리: revenue rank 153 of 287, share 0.1%.

153 / 2870.1%revenue share

Who dominates this industry?

  1. 1삼성바이오로직스7.3%
  2. 2셀트리온5.7%
  3. 3녹십자홀딩스3.5%
  4. 4유한양행3.3%
  5. 5대웅3.1%
  6. 6조아제약0.1%

Concentration

DistributedCR3 16.6%
HHI 202287 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
31.61
Direction
확대
Level
넓음
Years
7

Value lens

P90/P10
13.9
Median P/B
1.47
Level
넓음
n
263

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-15.5%
Interest coverage
-8.7x
Return on equity (ROE)
-30.6%

Operating margin −5pp

Operating loss
Interest coverageBase -8.7x adverse case -11.5x
Return on equity (ROE)Base -30.6% adverse case -44.5%

Revenue −15%

Interest coverage risk
Interest coverageBase -8.7x adverse case -7.4x
Return on equity (ROE)Base -30.6% adverse case -29.8%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -8.7x adverse case -5.1x
Return on equity (ROE)Base -30.6% adverse case -37%

Interest coverage limit

Already below the limit by 17.3pp

Interest coverage limit at an operating margin of 1.8%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-03-13

Suppliers disclosed by the company in its 2026-03-13 annual report.

Purchase amount

KRW 100m
  1. Actives
    KRW 145.5T
  2. Bio
    KRW 145.5T
  3. Diosmin
    KRW 145.5T
  4. HEALTHTECH
    KRW 145.5T
  5. Green
    KRW 54.2T
  6. Powder
    KRW 54.2T
  7. Tea
    KRW 54.2T
  8. 없음
    KRW 54.2T
  9. Complex
    KRW 21.7T
  10. Ferric
    KRW 21.7T

+8 more with disclosed amounts — included in coverage

Suppliers without disclosed amount

FerritinVATFerrittinTroxerutinArgininePhendimetrazineTartrateBetaineHydrochloride

Connections

AI-extracted related companies · for reference

🔗 See in the full market map →

Recent filings

ChoA Pharmaceutical's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

About ChoA Pharmaceutical
What technical signals does ChoA Pharmaceutical (034940) have?
ChoA Pharmaceutical current technical signals: no active technical signal.
Is ChoA Pharmaceutical a cup-and-handle pattern?
No. ChoA Pharmaceutical has no valid cup-and-handle signal right now.
What are ChoA Pharmaceutical's financials and valuation?
ChoA Pharmaceutical's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy